PDCD1 and diffuse large B-cell lymphoma: The poor results of anti-PD-1/anti-PD-L1 ICIs in unselected cases of DLBCL suggest that if there is any benefit in a particular subgroup, this may be lost in the heterogeneity of the disease and the trial design.